Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;15(5):e801-e807.
doi: 10.1016/j.clgc.2017.04.013. Epub 2017 Apr 26.

Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital

Diletta Bianchini  1 , David Lorente  2 , Pasquale Rescigno  3 , Zafeiris Zafeiriou  3 , Elena Psychopaida  3 , Hazel O'Sullivan  3 , Mervyn Alaras  3 , Michael Kolinsky  3 , Semini Sumanasuriya  1 , Mariane Sousa Fontes  1 , Joaquin Mateo  3 , Raquel Perez Lopez  3 , Nina Tunariu  1 , Nikolaos Fotiadis  1 , Pardeep Kumar  1 , Alison Tree  1 , Nicholas Van As  1 , Vincent Khoo  1 , Chris Parker  3 , Rosalind Eeles  3 , Alan Thompson  1 , David Dearnaley  3 , Johann S de Bono  4
Affiliations

Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital

Diletta Bianchini et al. Clin Genitourin Cancer. 2017 Oct.

Abstract

Background: The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) on overall survival (OS) hypothesizing that this could improve outcome through better local disease control and the induction of an antitumor immune response (abscopal effect).

Patients and methods: M1 at diagnosis PCa patients referred to the Prostate Targeted Therapy Group at the Royal Marsden between June 2003 and December 2013 were identified. LRT was defined as either surgery, radiotherapy (RT) or transurethral prostatectomy (TURP) administered to the primary tumor at any time point from diagnosis to death. Kaplan-Meier analyses generated OS data. The association between LRT and OS was evaluated in univariate (UV) and multivariate (MV) Cox regression models.

Results: Overall 300 patients were identified; 192 patients (64%) experienced local symptoms at some point during their disease course; 72 patients received LRT (56.9% TURP, 52.7% RT). None of the patients were treated with prostatectomy. LRT was more frequently performed in patients with low volume disease (35.4% vs. 16.2%; P < .001), lower prostate-specific antigen (PSA) level at diagnosis (median PSA: 75 vs. 184 ng/mL; P = .005) and local symptoms (34.2% vs. 4.8%; P < .001). LRT was associated in UV and MV analysis with longer OS (62.1 vs. 55.8 months; hazard ratio [HR], 0.74; P = .044), which remained significant for RT (69.4 vs. 55.1 months; HR, 0.54; P = .002) but not for TURP. RT was associated with better OS independent of disease volume at diagnosis.

Conclusion: These data support the conduct of randomized phase III trials to evaluate the benefit of local control in patients with M1 disease at diagnosis.

Keywords: Abscopal effect; Local disease; Local treatment; Metastatic CRPC; Radiotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Locoregional Treatment (LRT) and Survival (Transurethral Prostatectomy [TURP] + Radiotherapy [RT]). (B) LRT and Survival (TURP Only). (C) LRT and Survival (RT Only)
See this image and copyright information in PMC

References

    1. Sweeney C.J., Chen Y.H., Carducci M. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–746. - PMC - PubMed
    1. James N.D., Sydes M.R., Clarke N.W. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–1177. - PMC - PubMed
    1. Parker C.C., Sydes M.R., Mason M.D. Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. BJU Int. 2013;111:697–699. - PubMed
    1. Culp S.H., Schellhammer P.F., Williams M.B. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumour? A SEER-based study. Eur Urol. 2014;65:1058–1066. - PubMed
    1. Fossati N., Trinh Q.D., Sammon J. Identifying optimal candidates for local treatment of the primary tumour among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol. 2015;67:3–6. - PubMed

Publication types

Substances